Indication
Treatment of X-linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease.
Medicine details
- Medicine name:
- burosumab (Crysvita)
- SMC ID:
- SMC2588
- Pharmaceutical company
- Kyowa Kirin
- BNF chapter
- Endocrine system
- Submission type
- Ultra-orphan reassessment
- Publication due date:
- 15 January 2024
- SMC meeting date:
- 05 December 2023
- Patient group submission deadline:
- 02 October 2023